S100A9-Targeted Cowpea Mosaic Virus as a Prophylactic and Therapeutic Immunotherapy against Metastatic Breast Cancer and Melanoma.
S100A9-Targeted Cowpea Mosaic Virus as a Prophylactic and Therapeutic Immunotherapy against Metastatic Breast Cancer and Melanoma.
复制标题
DOI：
10.1002/advs.202101796
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Steinmetz NF
中科院分区：
文献类型：
--
作者：
Chung YH;Park J;Cai H;Steinmetz NF
转移性癌症的预后和治疗仍然是肿瘤学中最困难和最具挑战性的领域之一。治疗通常包括化疗药物，由于耐药性、不良反应和剂量限制性毒性，化疗药物可能无效。因此，已经研究了新的方法，如免疫疗法，以改善患者的预后并最大限度地减少副作用。S100A9是一种与肿瘤转移、进展和侵袭性有关的钙结合蛋白，可将肿瘤微环境调节至免疫抑制状态。S100A9在转移前小生境以及肿瘤后发展中的免疫细胞中表达并分泌，因此使其成为预防和治疗的合适靶点。在以前的工作中，它表明，豇豆花叶病毒（CPMV）作为一种佐剂时，给予瘤内。在这里，证明了全身施用的S100A9靶向CPMV返回肺部，导致先天免疫细胞的募集。这种方法对黑色素瘤和乳腺癌的肺转移在预防和治疗上都是有效的。目前的研究将促进和加速下一代靶向免疫疗法的开发，即在原发性乳腺肿瘤手术后预防转移的生长，以及治疗已确定的转移性疾病的疗法。转移性癌症仍然是肿瘤学的主要挑战之一。研究表明，豇豆花叶病毒（CPMV）直接注射到肿瘤中具有免疫刺激作用。目前的工作利用S100A9靶向CPMV作为针对乳腺癌和黑色素瘤转移模型的免疫预防和治疗方法。
Prognosis and treatment of metastatic cancer continues to be one of the most difficult and challenging areas of oncology. Treatment usually consists of chemotherapeutics, which may be ineffective due to drug resistance, adverse effects, and dose‐limiting toxicity. Therefore, novel approaches such as immunotherapy have been investigated to improve patient outcomes and minimize side effects. S100A9 is a calcium‐binding protein implicated in tumor metastasis, progression, and aggressiveness that modulates the tumor microenvironment into an immunosuppressive state. S100A9 is expressed in and secreted by immune cells in the pre‐metastatic niche, as well as, post‐tumor development, therefore making it a suitable targeted for prophylaxis and therapy. In previous work, it is demonstrated that cowpea mosaic virus (CPMV) acts as an adjuvant when administered intratumorally. Here, it is demonstrated that systemically administered, S100A9‐targeted CPMV homes to the lungs leading to recruitment of innate immune cells. This approach is efficacious both prophylactically and therapeutically against lung metastasis from melanoma and breast cancer. The current research will facilitate and accelerate the development of next‐generation targeted immunotherapies administered as prophylaxis, that is, after surgery of a primary breast tumor to prevent outgrowth of metastasis, as well as, therapy to treat established metastatic disease. Metastatic cancer continues to be one of the main challenges of oncology. It is demonstrated that cowpea mosaic virus (CPMV) is immunostimulatory when injected directly into tumors. The current work utilizes S100A9‐targeted CPMV as both an immunoprophylaxis and therapeutic approach against metastatic models of breast cancer and melanoma.
登录
查看更多内容
影响因子：
4.6
作者：
Bankhead P;Loughrey MB;Fernández JA;Dombrowski Y;McArt DG;Dunne PD;McQuaid S;Gray RT;Murray LJ;Coleman HG;James JA;Salto-Tellez M;Hamilton PW
通讯作者：
Hamilton PW
DOI：
10.1164/rccm.201304-0803oc
发表时间：
2013-11-01
影响因子：
24.7
作者：
Gopal, Radha;Monin, Leticia;Khader, Shabaana A.
通讯作者：
Khader, Shabaana A.
影响因子：
2.7
作者：
Chen, Siying;Yang, Jin;Lyu, Jun
通讯作者：
Lyu, Jun
综述中的黑色素瘤治疗。
影响因子：
7.2
作者：
Domingues B;Lopes JM;Soares P;Pópulo H
通讯作者：
Pópulo H
影响因子：
4.9
作者：
Hoopes, P. Jack;Wagner, Robert J.;Fiering, Steven N.
通讯作者：
Fiering, Steven N.